Cellular networks controlling T cell persistence in adoptive cell therapy

JD Chan; J Lai; CY Slaney; A Kallies; PA Beavis; PK Darcy

Journal article

Cellular networks controlling T cell persistence in adoptive cell therapy

JD Chan, J Lai, CY Slaney, A Kallies, PA Beavis, PK Darcy

Nature Reviews Immunology | NATURE PORTFOLIO | Published : 2021

DOI: 10.1038/s41577-021-00539-6

Abstract

The antitumour activity of endogenous or adoptively transferred tumour-specific T cells is highly dependent on their differentiation status. It is now apparent that less differentiated T cells compared with fully differentiated effector T cells have better antitumour therapeutic effects owing to their enhanced capacity to expand and their long-term persistence. In patients with cancer, the presence of endogenous or adoptively transferred T cells with stem-like memory or precursor phenotype correlates with improved therapeutic outcomes. Advances in our understanding of T cell differentiation states at the epigenetic and transcriptional levels have led to the development of novel methods to ge..

View full abstract

University of Melbourne Researchers

Related Projects (3)

NEW STRATEGIES FOR ENHANCING CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY FOR CANCER

The role of the immune system in cancer is now recognised as highly important, highlighted by the success of immunotherapy in patients. Yet ..

TRANSCRIPTIONAL AND METABOLIC REGULATION OF EFFECTOR AND MEMORY LYMPHOCYTE DIFFERENTIATION

I am an internationally recognized expert in the field of lymphocyte biology. My work has shed light on antibody production, T cell response..

TARGETING ADENOSINE MEDIATED IMMUNOSUPPRESSION TO ENHANCE CAR T CELL ACTIVITY IN BREAST CANCER

Grants

Awarded by Cancer Council Victoria

Funding Acknowledgements

The authors acknowledge funding support from the National Health and Medical Research Council of Australia (NHMRC), the Australian National Breast Cancer Foundation, the Cancer Council of Victoria and the ClearBridge Foundation. J.D.C. is supported by an Australian Government Research Training Program scholarship and a Peter MacCallum Cancer Foundation postgraduate scholarship. J.L. is a recipient of a US Cancer Research Institute Irvington postdoctoral fellowship (award no. 3530). A.K. is supported by an NHMRC senior research fellowship (APP1139607). P.A.B. is supported by an Australian National Breast Cancer Foundation fellowship (ECF-17-005) and a Victorian Cancer Agency Research fellowship (MCRF20011). P.K.D. is supported by an NHMRC senior research fellowship (APP1136680).